1. Home
  2. VBNK vs CTNM Comparison

VBNK vs CTNM Comparison

Compare VBNK & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VersaBank

VBNK

VersaBank

HOLD

Current Price

$16.33

Market Cap

499.0M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.77

Market Cap

575.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VBNK
CTNM
Founded
1980
2009
Country
Canada
United States
Employees
N/A
N/A
Industry
Commercial Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
499.0M
575.3M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
VBNK
CTNM
Price
$16.33
$14.77
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$13.00
$18.60
AVG Volume (30 Days)
42.3K
251.6K
Earning Date
03-04-2026
03-05-2026
Dividend Yield
0.45%
N/A
EPS Growth
N/A
N/A
EPS
0.64
N/A
Revenue
$85,792,576.00
N/A
Revenue This Year
$37.01
N/A
Revenue Next Year
$30.71
N/A
P/E Ratio
$25.63
N/A
Revenue Growth
7.44
N/A
52 Week Low
$8.51
$3.35
52 Week High
$16.99
$16.01

Technical Indicators

Market Signals
Indicator
VBNK
CTNM
Relative Strength Index (RSI) 56.77 62.68
Support Level $15.88 $14.59
Resistance Level $16.99 $16.01
Average True Range (ATR) 0.37 1.09
MACD -0.05 0.02
Stochastic Oscillator 41.14 68.40

Price Performance

Historical Comparison
VBNK
CTNM

About VBNK VersaBank

VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: